The aptamer, modified A10 in the chimeras mediates cell type-specific binding to human PSMA, a cell-surface receptor expressing in prostate cancer cells, whereas, the therapeutic CRISPR/Cas9 target PLK1. This evidence concerns the gene PLK1 and prostate cancer.